ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 763,54
0,70%
Dow Jones
43 487,83
0,78%
DAX
21 047,63
0,72%
Brent Oil
79,00
-1,51%
Bitcoin
107 495,32
4,25%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Amphastar Pharmaceuticals Inc (AMPH)

  7. Amphastar Pharmaceuticals Inc (AMPH) Actualités

AMPH

Amphastar Pharmaceuticals (AMPH)

Amphastar Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AMPH
DateHeureSourceTitreSymboleSociété
16/12/202423h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMPHAmphastar Pharmaceuticals Inc
12/11/202419h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMPHAmphastar Pharmaceuticals Inc
07/11/202422h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMPHAmphastar Pharmaceuticals Inc
06/11/202422h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMPHAmphastar Pharmaceuticals Inc
29/02/202422h53Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AMPHAmphastar Pharmaceuticals Inc
09/02/202423h21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AMPHAmphastar Pharmaceuticals Inc
12/09/202318h10Dow Jones NewsAmphastar Pharmaceuticals Shares Down 9% After Private Notes OfferingNASDAQ:AMPHAmphastar Pharmaceuticals Inc
16/08/202323h24Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AMPHAmphastar Pharmaceuticals Inc
21/06/202323h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
15/06/202322h08Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
06/06/202312h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
09/05/202322h55Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
24/04/202313h42Dow Jones NewsEli Lilly to Sell Baqsimi Product to AmphastarNASDAQ:AMPHAmphastar Pharmaceuticals Inc
24/04/202312h45PR Newswire (US)Lilly to Divest BAQSIMI to AmphastarNASDAQ:AMPHAmphastar Pharmaceuticals Inc
14/04/202322h22Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
14/04/202322h10Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
01/03/202322h14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
09/02/202317h09Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
09/08/202212h55TipRanksNeedham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
09/06/202220h05TipRanksAmphastar Pharmaceuticals (AMPH) Receives a Hold from NeedhamNASDAQ:AMPHAmphastar Pharmaceuticals Inc
24/05/202218h25TipRanksNeedham Maintains a Hold Rating on Amphastar Pharmaceuticals (AMPH)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
14/04/202222h32Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
13/04/202217h35TipRanksNeedham Maintains Their Hold Rating on Amphastar Pharmaceuticals (AMPH)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
08/04/202216h45TipRanksAmphastar Pharmaceuticals (AMPH) Gets a Hold Rating from NeedhamNASDAQ:AMPHAmphastar Pharmaceuticals Inc
09/11/202122h34Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:AMPHAmphastar Pharmaceuticals Inc
15/06/202122h05GlobeNewswire Inc.Amphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation ConferenceNASDAQ:AMPHAmphastar Pharmaceuticals Inc
27/05/202112h00GlobeNewswire Inc.Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare ConferenceNASDAQ:AMPHAmphastar Pharmaceuticals Inc
07/05/202122h05GlobeNewswire Inc.Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin SubsidiaryNASDAQ:AMPHAmphastar Pharmaceuticals Inc
06/05/202122h05GlobeNewswire Inc.Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021NASDAQ:AMPHAmphastar Pharmaceuticals Inc
03/05/202112h00GlobeNewswire Inc.Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate InjectionNASDAQ:AMPHAmphastar Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AMPH

Dernières Valeurs Consultées

NASDAQ
ATOM
Atomera
TG
3PM
Infinity Lithium
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés